Quick Takeaways
- This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
- 4 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 05 Apr 2024, 18:59.
Michael Egholm - 05 Jan 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)
- Signature
- /s/ Michael Egholm by Agnieszka Gallagher, Attorney-in-Fact
- Issuer symbol
- LAB
- Transactions as of
- 05 Jan 2024
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 05 Apr 2024, 18:59:07 UTC
- Previous filing
- 06 Apr 2023
- Next filing
- 09 Apr 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 05 Apr 2024."
What Changed
- Previous filing in this sequence was filed on 06 Apr 2023.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LAB | Common Stock | Award | $0 | +9,006 | +4.2% | $0.000000 | 225,518 | 05 Jan 2024 | Direct | F1 |
| transaction | LAB | Common Stock | Options Exercise | $0 | +196,512 | +87% | $0.000000 | 422,030 | 04 Apr 2024 | Direct | |
| transaction | LAB | Common Stock | Award | $0 | +212,126 | +50% | $0.000000 | 634,156 | 05 Apr 2024 | Direct | F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LAB | Restricted Stock Units | Options Exercise | $0 | -196,512 | -33% | $0.000000 | 393,025 | 04 Apr 2024 | Common Stock | 196,512 | Direct | F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger. |
| F2 | On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024. |
| F3 | Each RSU represents the contingent right to receive one share of the Issuer's common stock. |
| F4 | On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. |